EUVIMEDEUVIMED entdecken
MetaanalyseSystematische Übersicht

Prophylactic aspirin intake and breast cancer risk; A systematic review and meta-analysis of observational cohort studies

Martyna Bakierzynska, Ms Carolyn Cullinane, Henry Paul Redmond, Mark Corrigan

European Journal of Surgical Oncology · 2023

DOI: 10.1016/j.ejso.2023.05.015 ↗

Kurz gefasst

Metaanalyse in der Zeitschrift European Journal of Surgical Oncology, 2023. Verfasst von Martyna Bakierzynska und 3 weiteren Autor:innen. Beteiligte Einrichtung: University College Cork, Cork, Ireland. Electronic address: mbakierzynska1307@gmail.com. Hauptthemen laut MEDLINE: Aspirin, Breast Neoplasms. Die Arbeit wurde bisher 10-mal zitiert (Crossref) und nennt 46 Literaturangaben.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Breast Cancer (BC) is the most common cancer amongst women. The chemo-preventative effects of aspirin on breast cancer have been demonstrated in several longitudinal studies however previous meta-analysis have shown inconsistent results. This study aimed to assess the relationship between aspirin use and BC risk, and to determine if there is a dose-response relationship between aspirin and BC risk. Studies incorporating BC risk with aspirin use published within the last twenty years were included. The study report is based on the guidelines of Preferred Reporting Items for Systematic Reviews and Meta-Analysis (PRISMA) and Meta-Analysis of Observational Studies in Epidemiology. Twenty-eight cohort studies that reported BC incidence during a follow up of 4.4-32 years were included. Compared to non-users, aspirin users had a reduced risk of BC (HR = 0.91, c.i 0.81-0.97, p = 0.002). There was no obvious association between BC risk reduction and aspirin dose (HR = 0.94, c.i 0.85-1.04) or duration (HR = 0.86, c.i 0.71-1.03). Frequency, however, was associated with a reduced risk of BC (HR = 0.90, c.i 0.82-0.98). A risk reduction was observed in oestrogen receptor (ER) positive tumours (HR = 0.90, c.i 0.86-0.96, p = 0.0004) while no relationship was observed with ER negative tumours (HR = 0.94, c.i 0.85-1.05). This meta-analysis found an association between aspirin intake and BC risk reduction. A more favourable outcome was noted with ingestion of greater than 6 tablets of aspirin per week. Aspirin had a significant risk reduction in patients with ER positive tumours compared to ER negative BC.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

AspirinBreast NeoplasmsHumansFemaleRiskCohort StudiesIncidenceObservational Studies as Topic

Stichwörter der Autor:innen

AspirinBreast cancerChemopreventionMeta-analysis

Substanzen

Aspirin

Autor:innen und Institutionen

  • University College Cork, Cork, Ireland. Electronic address: mbakierzynska1307@gmail.com.
  • Department of Surgery, Cork University Hospital, Cork, T12 DC4A, Ireland.
  • Department of Surgery, Cork University Hospital, University College Cork, Cork, Ireland.

Zitieren

APA

Bakierzynska, M., Cullinane, M. C., Redmond, H. P., & Corrigan, M. (2023). Prophylactic aspirin intake and breast cancer risk; A systematic review and meta-analysis of observational cohort studies. European Journal of Surgical Oncology. https://doi.org/10.1016/j.ejso.2023.05.015

Vancouver

Bakierzynska M, Cullinane MC, Redmond HP, Corrigan M. Prophylactic aspirin intake and breast cancer risk; A systematic review and meta-analysis of observational cohort studies. European Journal of Surgical Oncology. 2023. doi:10.1016/j.ejso.2023.05.015

BibTeX
@article{Bakierzynska2023,
  author = {Bakierzynska, Martyna and Cullinane, Ms Carolyn and Redmond, Henry Paul and Corrigan, Mark},
  title = {Prophylactic aspirin intake and breast cancer risk; A systematic review and meta-analysis of observational cohort studies},
  journal = {European Journal of Surgical Oncology},
  year = {2023},
  doi = {10.1016/j.ejso.2023.05.015}
}
Kostenlos starten →